Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 729352, 12 pages
http://dx.doi.org/10.1155/2015/729352
Review Article

Functional Diversity of Fibroblast Growth Factors in Bone Formation

Department of Calcified Tissue Biology, Hiroshima University Institute of Biomedical & Health Sciences, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8553, Japan

Received 20 June 2014; Revised 23 August 2014; Accepted 31 August 2014

Academic Editor: Martina Rauner

Copyright © 2015 Yuichiro Takei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. X. Feng and J. M. McDonald, “Disorders of bone remodeling,” Annual Review of Pathology, vol. 6, pp. 121–145, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Ferron, M. D. McKee, R. L. Levine, P. Ducy, and G. Karsenty, “Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice,” Bone, vol. 50, no. 2, pp. 568–575, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. L. M. Calvi, G. B. Adams, K. W. Weibrecht et al., “Osteoblastic cells regulate the haematopoietic stem cell niche,” Nature, vol. 425, no. 6960, pp. 841–846, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Zhang, C. Niu, L. Ye et al., “Identification of the haematopoietic stem cell niche and control of the niche size,” Nature, vol. 425, no. 6960, pp. 836–841, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Iwasaki and T. Suda, “Cancer stem cells and their niche,” Cancer Science, vol. 100, no. 7, pp. 1166–1172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Takeda, F. Elefteriou, R. Levasseur et al., “Leptin regulates bone formation via the sympathetic nervous system,” Cell, vol. 111, no. 3, pp. 305–317, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Collet, C. Schiltz, V. Geoffroy, L. Maroteaux, J.-M. Launay, and M.-C. de Vernejoul, “The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation,” The FASEB Journal, vol. 22, no. 2, pp. 418–427, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Kuro-o, “Endocrine FGFs and Klothos: emerging concepts,” Trends in Endocrinology & Metabolism, vol. 19, no. 7, pp. 239–245, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Wang, Y. Yoshiko, R. Yamamoto et al., “Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro,” Journal of Bone and Mineral Research, vol. 23, no. 6, pp. 939–948, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. R. T. Böttcher and C. Niehrs, “Fibroblast growth factor signaling during early vertebrate development,” Endocrine Reviews, vol. 26, no. 1, pp. 63–77, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Thisse and C. Thisse, “Functions and regulations of fibroblast growth factor signaling during embryonic development,” Developmental Biology, vol. 287, no. 2, pp. 390–402, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Kurosu and M. Kuro-O, “Endocrine fibroblast growth factors as regulators of metabolic homeostasis,” BioFactors, vol. 35, no. 1, pp. 52–60, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Mohammadi, S. K. Olsen, and O. A. Ibrahimi, “Structural basis for fibroblast growth factor receptor activation,” Cytokine and Growth Factor Reviews, vol. 16, no. 2, pp. 107–137, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Dailey, D. Ambrosetti, A. Mansukhani, and C. Basilico, “Mechanisms underlying differential responses to FGF signaling,” Cytokine and Growth Factor Reviews, vol. 16, no. 2, pp. 233–247, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Hacohen, S. Kramer, D. Sutherland, Y. Hiromi, and M. A. Krasnow, “Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways,” Cell, vol. 92, no. 2, pp. 253–263, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Fürthauer, F. Reifers, M. Brand, B. Thisse, and C. Thisse, “Sprouty4 acts in vivo as a feedback-induced antagonist of FGF signaling in zebrafish,” Development, vol. 128, no. 12, pp. 2175–2186, 2001. View at Google Scholar · View at Scopus
  17. M. Fürthauer, W. Lin, S.-L. Ang, B. Thisse, and C. Thisse, “Sef is a feedback-induced antagonist of RAs/MAPK-mediated FGF signalling,” Nature Cell Biology, vol. 4, no. 2, pp. 170–174, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Hirate and H. Okamoto, “Canopy1, a novel regulator of FGF signaling around the midbrain-hindbrain boundary in zebrafish,” Current Biology, vol. 16, no. 4, pp. 421–427, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Matsui, S. Thitamadee, T. Murata et al., “Canopy1, a positive feedback regulator of FGF signaling, controls progenitor cell clustering during Kupffer's vesicle organogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 24, pp. 9881–9886, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Debiais, M. Hott, A. M. Graulet, and P. J. Marie, “The effects of fibroblast growth factor-2 on human neonatal calvaria osteoblastic cells are differentiation stage specific,” Journal of Bone and Mineral Research, vol. 13, no. 4, pp. 645–654, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Okazaki, T. Kurokawa, K. Nakamura, T. Matsushita, K. Mamada, and H. Kawaguchi, “Stimulation of bone formation by recombinant fibroblast growth factor-2 in callotasis bone lengthening of rabbits,” Calcified Tissue International, vol. 64, no. 6, pp. 542–546, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Kitamura, M. Akamatsu, M. MacHigashira et al., “FGF-2 stimulates periodontal regeneration: results of a multi-center randomized clinical trial,” Journal of Dental Research, vol. 90, no. 1, pp. 35–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Nagai, R. Tsukuda, and H. Mayahara, “Effects of basic fibroblast growth factor (bFGF) on bone formation in growing rats,” Bone, vol. 16, no. 3, pp. 367–373, 1995. View at Publisher · View at Google Scholar · View at Scopus
  24. C. R. Dunstan, R. Boyce, B. F. Boyce et al., “Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats,” Journal of Bone and Mineral Research, vol. 14, no. 6, pp. 953–959, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. J. I. Aguirre, M. E. Leal, M. F. Rivera, S. M. Vanegas, M. Jorgensen, and T. J. Wronski, “Effects of basic fibroblast growth factor and a prostaglandin E2 receptor subtype 4 agonist on osteoblastogenesis and adipogenesis in aged ovariectomized rats,” Journal of Bone and Mineral Research, vol. 22, no. 6, pp. 877–888, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Montero, Y. Okada, M. Tomita et al., “Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation,” Journal of Clinical Investigation, vol. 105, no. 8, pp. 1085–1093, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Naganawa, L. Xiao, J. D. Coffin et al., “Reduced expression and function of bone morphogenetic protein-2 in bones of Fgf2 null mice,” Journal of Cellular Biochemistry, vol. 103, no. 6, pp. 1975–1988, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Xiao, T. Sobue, A. Esliger et al., “Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cells,” Bone, vol. 47, no. 2, pp. 360–370, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Xiao, P. Liu, X. Li et al., “Exported 18-kDa isoform of fibroblast growth factor-2 is a critical determinant of bone mass in mice,” Journal of Biological Chemistry, vol. 284, no. 5, pp. 3170–3182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. K. T. Tang, C. Capparelli, J. L. Stein et al., “Acidic fibroblast growth factor inhibits osteoblast differentiation in vitro: altered expression of collagenase, cell growth-related, and mineralization-associated genes,” Journal of Cellular Biochemistry, vol. 61, no. 1, pp. 152–166, 1996. View at Google Scholar
  31. D. L. Miller, S. Ortega, O. Bashayan, R. Basch, and C. Basilico, “Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice,” Molecular and Cellular Biology, vol. 20, no. 6, pp. 2260–2268, 2000. View at Google Scholar
  32. S. Kuroda, S. Kasugai, S. Oida, T. Iimura, K. Ohya, and T. Ohyama, “Anabolic effect of aminoterminally truncated fibroblast growth factor 4 (FGF4) on bone,” Bone, vol. 25, no. 4, pp. 431–437, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Bosetti, M. Leigheb, R. A. Brooks, F. Boccafoschi, and M. F. Cannas, “Regulation of osteoblast and osteoclast functions by FGF-6,” Journal of Cellular Physiology, vol. 225, no. 2, pp. 466–471, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. Y.-M. Jeon, S.-H. Kook, S.-J. Rho et al., “Fibroblast growth factor-7 facilitates osteogenic differentiation of embryonic stem cells through the activation of ERK/Runx2 signaling,” Molecular and Cellular Biochemistry, vol. 382, no. 1-2, pp. 37–45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Omoteyama and M. Takagi, “FGF8 regulates myogenesis and induces Runx2 expression and osteoblast differentiation in cultured cells,” Journal of Cellular Biochemistry, vol. 106, no. 4, pp. 546–552, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. V. Govindarajan and P. A. Overbeek, “FGF9 can induce endochondral ossification in cranial mesenchyme,” BMC Developmental Biology, vol. 6, article 7, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Kizhner, D. Ben-David, E. Rom, A. Yayon, and E. Livne, “Effects of FGF2 and FGF9 on osteogenic differentiation of bone marrow-derived progenitors,” In Vitro Cellular and Developmental Biology—Animal, vol. 47, no. 4, pp. 294–301, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. M. K. Hajihosseini, R. Duarte, J. Pegrum et al., “Evidence that Fgf10 contributes to the skeletal and visceral defects of an apert syndrome mouse model,” Developmental Dynamics, vol. 238, no. 2, pp. 376–385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Shimoaka, T. Ogasawara, A. Yonamine et al., “Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10,” The Journal of Biological Chemistry, vol. 277, no. 9, pp. 7493–7500, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Ohbayashi, M. Shibayama, Y. Kurotaki et al., “FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis,” Genes and Development, vol. 16, no. 7, pp. 870–879, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Chen and C.-X. Deng, “Roles of FGF signaling in skeletal development and human genetic diseases,” Frontiers in Bioscience, vol. 10, no. 2, pp. 1961–1976, 2005. View at Google Scholar · View at Scopus
  42. G. M. Morriss-Kay and A. O. M. Wilkie, “Growth of the normal skull vault and its alteration in craniosynostosis: insights from human genetics and experimental studies,” Journal of Anatomy, vol. 207, no. 5, pp. 637–653, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. D. M. Ornitz and P. J. Marie, “FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease,” Genes & Development, vol. 16, no. 12, pp. 1446–1465, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. D. M. Ornitz, “FGF signaling in the developing endochondral skeleton,” Cytokine and Growth Factor Reviews, vol. 16, no. 2, pp. 205–213, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. T. P. Yamaguchi, K. Harpal, M. Henkemeyer, and J. Rossant, “fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation,” Genes and Development, vol. 8, no. 24, pp. 3032–3044, 1994. View at Publisher · View at Google Scholar · View at Scopus
  46. A. L. Jacob, C. Smith, J. Partanen, and D. M. Ornitz, “Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation,” Developmental Biology, vol. 296, no. 2, pp. 315–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. E. W. Jabs, X. Li, A. F. Scott et al., “Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2,” Nature Genetics, vol. 8, no. 3, pp. 275–279, 1994. View at Publisher · View at Google Scholar · View at Scopus
  48. A. O. M. Wilkie, S. F. Slaney, M. Oldridge et al., “Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome,” Nature Genetics, vol. 9, no. 2, pp. 165–172, 1995. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Wang, R. Xiao, F. Yang et al., “Abnormalities in cartilage and bone development in the Apert syndrome FGFR2+/S252W mouse,” Development, vol. 132, no. 5, pp. 3537–3548, 2005. View at Publisher · View at Google Scholar
  50. H. Miraoui, K. Oudina, H. Petite, Y. Tanimoto, K. Moriyama, and P. J. Marie, “Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling,” The Journal of Biological Chemistry, vol. 284, no. 8, pp. 4897–4904, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. F. Rousseau, J. Bonaventure, L. Legeai-Mallet et al., “Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia,” Nature, vol. 371, no. 6494, pp. 252–254, 1994. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Muenke, K. W. Gripp, D. M. McDonald-McGinn et al., “A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome,” The American Journal of Human Genetics, vol. 60, no. 3, pp. 555–564, 1997. View at Google Scholar · View at Scopus
  53. G. A. Meyers, S. J. Orlow, I. R. Munro, K. A. Przylepa, and E. W. Jabs, “Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans,” Nature Genetics, vol. 11, no. 4, pp. 462–464, 1995. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Deng, A. Wynshaw-Boris, F. Zhou, A. Kuo, and P. Leder, “Fibroblast growth factor receptor 3 is a negative regulator of bone growth,” Cell, vol. 84, no. 6, pp. 911–921, 1996. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Weizmann, A. Tong, A. Reich, O. Genina, A. Yayon, and E. Monsonego-Ornan, “FGF upregulates osteopontin in epiphyseal growth plate chondrocytes: implications for endochondral ossification,” Matrix Biology, vol. 24, no. 8, pp. 520–529, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Cool, R. Jackson, P. Pincus, I. Dickinson, and V. Nurcombe, “Fibroblast growth factor receptor 4 (FGFR4) expression in newborn murine calvaria and primary osteoblast cultures,” International Journal of Developmental Biology, vol. 46, no. 4, pp. 519–523, 2002. View at Google Scholar · View at Scopus
  57. X. Bai, D. Miao, J. Li, D. Goltzman, and A. C. Karaplis, “Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders,” Endocrinology, vol. 145, no. 11, pp. 5269–5279, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Larsson, R. Marsell, E. Schipani et al., “Transgenic mice expressing fibroblast growth factor 23 under the control of the α1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis,” Endocrinology, vol. 145, no. 7, pp. 3087–3094, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Shimada, M. Kakitani, Y. Yamazaki et al., “Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism,” The Journal of Clinical Investigation, vol. 113, no. 4, pp. 561–568, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. L. D. Quarles, “Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism,” Nature Reviews Endocrinology, vol. 8, no. 5, pp. 276–286, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. K. E. White, W. E. Evans, J. L. H. O'Riordan et al., “Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23,” Nature Genetics, vol. 26, no. 3, pp. 345–348, 2000. View at Publisher · View at Google Scholar · View at Scopus
  62. T. Shimada, S. Mizutani, T. Muto et al., “Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 11, pp. 6500–6505, 2001. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Yoshiko, H. Wang, T. Minamizaki et al., “Mineralized tissue cells are a principal source of FGF23,” Bone, vol. 40, no. 6, pp. 1565–1573, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Mirams, B. G. Robinson, R. S. Mason, and A. E. Nelson, “Bone as a source of FGF23: regulation by phosphate?” Bone, vol. 35, no. 5, pp. 1192–1199, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. R. Masuyama, I. Stockmans, S. Torrekens et al., “Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts,” The Journal of Clinical Investigation, vol. 116, no. 12, pp. 3150–3159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Liu, W. Tang, J. Zhou, L. Vierthaler, and L. D. Quarles, “Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 293, no. 6, pp. E1636–E1644, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. I. Urakawa, Y. Yamazaki, T. Shimada et al., “Klotho converts canonical FGF receptor into a specific receptor for FGF23,” Nature, vol. 444, no. 7120, pp. 770–774, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Kurosu, Y. Ogawa, M. Miyoshi et al., “Regulation of fibroblast growth factor-23 signaling by Klotho,” Journal of Biological Chemistry, vol. 281, no. 10, pp. 6120–6123, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Imura, Y. Tsuji, M. Murata et al., “α-klotho as a regulator of calcium homeostasis,” Science, vol. 316, no. 5831, pp. 1615–1618, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Gattineni, C. Bates, K. Twombley et al., “FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1,” The American Journal of Physiology—Renal Physiology, vol. 297, no. 2, pp. F282–F291, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Saito, K. Kusano, M. Kinosaki et al., “Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1α,25-dihydroxyvitamin D3 production,” The Journal of Biological Chemistry, vol. 278, no. 4, pp. 2206–2211, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Liu, W. Tang, J. Zhou et al., “Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D,” Journal of the American Society of Nephrology, vol. 17, no. 5, pp. 1305–1315, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. R. Yamamoto, T. Minamizaki, Y. Yoshiko et al., “1α,25-dihydroxyvitamin D3 acts predominately in mature osteoblasts under conditions of high extracellular phosphate to increase fibroblast growth factor 23 production in vitro,” Journal of Endocrinology, vol. 206, no. 3, pp. 279–286, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. I. Z. Ben-Dov, H. Galitzer, V. Lavi-Moshayoff et al., “The parathyroid is a target organ for FGF23 in rats,” The Journal of Clinical Investigation, vol. 117, no. 12, pp. 4003–4008, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. H. Olauson, K. Lindberg, R. Amin et al., “Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion,” PLoS Genetics, vol. 9, no. 12, Article ID e1003975, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. Rhee, N. Bivi, E. Farrow et al., “Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo,” Bone, vol. 49, no. 4, pp. 636–643, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Gattineni, K. Twombley, R. Goetz, M. Mohammadi, and M. Baum, “Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4,” The American Journal of Physiology—Renal Physiology, vol. 301, no. 2, pp. F371–F377, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. N. Arai-Nunota, M. Mizobuchi, H. Ogata et al., “Intravenous phosphate loading increases fibroblast growth factor 23 in uremic rats,” PLoS ONE, vol. 9, no. 3, Article ID e91096, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Kawai, S. Kinoshita, S. Shimba, K. Ozono, and T. Michigami, “Sympathetic activation induces skeletal Fgf23 expression in a circadian rhythm-dependent manner,” The Journal of Biological Chemistry, vol. 289, no. 3, pp. 1457–1466, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. R. C. Smith, L. M. O'Bryan, E. G. Farrow et al., “Circulating αKlotho influences phosphate handling by controlling FGF23 production,” Journal of Clinical Investigation, vol. 122, no. 12, pp. 4710–4715, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Kuro-o, Y. Matsumura, H. Aizawa et al., “Mutation of the mouse klotho gene leads to a syndrome resembling ageing,” Nature, vol. 390, no. 6655, pp. 45–51, 1997. View at Publisher · View at Google Scholar · View at Scopus
  82. Y. Takei, H. Yamamoto, T. Sato et al., “Stanniocalcin 2 is associated with ectopic calcification in α-klotho mutant mice and inhibits hyperphosphatemia-induced calcification in aortic vascular smooth muscle cells,” Bone, vol. 50, no. 4, pp. 998–1005, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. Q. Yuan, Y. Jiang, X. Zhao et al., “Increased osteopontin contributes to inhibition of bone mineralization in FGF23-deficient mice,” Journal of Bone and Mineral Research, vol. 29, no. 3, pp. 693–704, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. D. Sitara, S. Kim, M. S. Razzaque et al., “Genetic evidence of serum phosphate-independent functions of FGF-23 on bone,” PLoS Genetics, vol. 4, no. 8, Article ID e1000154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. Matsumura, H. Aizawa, T. Shiraki-Iida, R. Nagai, M. Kuro-O, and Y.-I. Nabeshima, “Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein,” Biochemical and Biophysical Research Communications, vol. 242, no. 3, pp. 626–630, 1998. View at Publisher · View at Google Scholar · View at Scopus
  86. T. Shiraki-Iida, H. Aizawa, Y. Matsumura et al., “Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein,” FEBS Letters, vol. 424, no. 1-2, pp. 6–10, 1998. View at Publisher · View at Google Scholar · View at Scopus
  87. V. Shalhoub, S. C. Ward, B. Sun et al., “Fibroblast growth factor 23 (FGF23) and α-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization,” Calcified Tissue International, vol. 89, no. 2, pp. 140–150, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Kawai, S. Kinoshita, A. Kimoto et al., “FGF23 suppresses chondrocyte proliferation in the presence of solubleα-klotho both in vitro and in vivo,” Journal of Biological Chemistry, vol. 288, no. 4, pp. 2414–2427, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. C. Faul, A. P. Amaral, B. Oskouei et al., “FGF23 induces left ventricular hypertrophy,” Journal of Clinical Investigation, vol. 121, no. 11, pp. 4393–4408, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. B. Angelin, T. E. Larsson, and M. Rudling, “Circulating fibroblast growth factors as metabolic regulators—a critical appraisal,” Cell Metabolism, vol. 16, no. 6, pp. 693–705, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Krejci, D. Krakow, P. B. Mekikian, and W. R. Wilcox, “Fibroblast growth factors 1, 2, 17, and 19 are the predominant FGF ligands expressed in human fetal growth plate cartilage,” Pediatric Research, vol. 61, no. 3, pp. 267–272, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. W. Wei, P. A. Dutchak, X. Wang et al., “Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 8, pp. 3143–3148, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. I. Delrieu, “The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism,” FEBS Letters, vol. 468, no. 1, pp. 6–10, 2000. View at Publisher · View at Google Scholar · View at Scopus
  94. P. Claus, F. Döring, S. Gringel et al., “Differential intranuclear localization of fibroblast growth factor-2 isoforms and specific interaction with the survival of motoneuron protein,” Journal of Biological Chemistry, vol. 278, no. 1, pp. 479–485, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. L. Xiao, T. Naganawa, J. Lorenzo, T. O. Carpenter, J. D. Coffin, and M. M. Hurley, “Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO,” The Journal of Biological Chemistry, vol. 285, no. 4, pp. 2834–2846, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Wolf, “Update on fibroblast growth factor 23 in chronic kidney disease,” Kidney International, vol. 82, no. 7, pp. 737–747, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. Z. Chen, X. Chen, J. Xie et al., “Fibroblast growth factor 23 is a predictor of aortic artery calcification in maintenance hemodialysis patients,” Renal Failure, vol. 35, no. 5, pp. 660–666, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. J. R. Montford, M. Chonchol, A. K. Cheung et al., “Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23,” American Journal of Nephrology, vol. 37, no. 3, pp. 183–190, 2013. View at Publisher · View at Google Scholar · View at Scopus